VEON (NASDAQ:VEON) reported $940.00 million in sales this quarter. This is a 54.19 percent decrease over sales of $2.05 billion the same period last year.
Avita Medical Raises FY22 Revenue Guidance From $30M To $33M-$34M Vs $30.63M Est.
2022 Revenue Guidance
Turning to guidance, full year 2022 commercial revenue (excluding BARDA revenues) is expected to be $33.0-34.0 million, an increase from our prior guidance of $30